secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-016015
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Q2 net loss $12.3M; positive LC-FAOD results; STRIDE enrollment two-thirds
--------------------------------------------------------------------------------

- Net loss $12.3M ($0.50/share) vs $9.2M ($0.43/share) in Q2 2021.
- Cash, cash equivalents, and short-term investments ~$127M as of June 30, 2022.
- R&D expenses $8.1M (up $1.8M YoY); G&A $4.3M (up $1.4M).
- Positive results from REN001 Phase 1b LC-FAOD study; plan to meet regulators.
- STRIDE pivotal PMM study enrollment two-thirds complete; on track for year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017022016015/0000950170-22-016015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017022016015/rphm-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer